Advanced MRI increases the diagnostic accuracy of recurrent glioblastoma: Single institution thresholds and validation of MR spectroscopy and diffusion weighted MR imaging
Language English Country Netherlands Media electronic-ecollection
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
27298760
PubMed Central
PMC4893011
DOI
10.1016/j.nicl.2016.02.016
PII: S2213-1582(16)30038-9
Knihovny.cz E-resources
- Keywords
- Apparent diffusion coefficient, Glioma, Imaging sensitivity, Recurrence, Spectroscopy,
- MeSH
- Choline metabolism MeSH
- Diffusion Magnetic Resonance Imaging * MeSH
- Adult MeSH
- Glioblastoma diagnostic imaging MeSH
- Cohort Studies MeSH
- Aspartic Acid analogs & derivatives metabolism MeSH
- Glutamic Acid metabolism MeSH
- Middle Aged MeSH
- Humans MeSH
- Magnetic Resonance Spectroscopy * MeSH
- Brain Neoplasms diagnostic imaging MeSH
- Statistics, Nonparametric MeSH
- Image Processing, Computer-Assisted MeSH
- ROC Curve MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Choline MeSH
- Aspartic Acid MeSH
- Glutamic Acid MeSH
- N-acetylaspartate MeSH Browser
The accurate identification of glioblastoma progression remains an unmet clinical need. The aim of this prospective single-institutional study is to determine and validate thresholds for the main metabolite concentrations obtained by MR spectroscopy (MRS) and the values of the apparent diffusion coefficient (ADC) to enable distinguishing tumor recurrence from pseudoprogression. Thirty-nine patients after the standard treatment of a glioblastoma underwent advanced imaging by MRS and ADC at the time of suspected recurrence - median time to progression was 6.7 months. The highest significant sensitivity and specificity to call the glioblastoma recurrence was observed for the total choline (tCho) to total N-acetylaspartate (tNAA) concentration ratio with the threshold ≥ 1.3 (sensitivity 100.0% and specificity 94.7%). The ADCmean value higher than 1313 × 10(- 6) mm(2)/s was associated with the pseudoprogression (sensitivity 98.3%, specificity 100.0%). The combination of MRS focused on the tCho/tNAA concentration ratio and the ADCmean value represents imaging methods applicable to early non-invasive differentiation between a glioblastoma recurrence and a pseudoprogression. However, the institutional definition and validation of thresholds for differential diagnostics is needed for the elimination of setup errors before implementation of these multimodal imaging techniques into clinical practice, as well as into clinical trials.
See more in PubMed
Ahmed R., Oborski M.J., Hwang M., Lieberman F.S., Mountz J.M. Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Cancer Manag. Res. 2014;6:149–170. PubMed PMC
Bulik M., Jancalek R., Vanicek J., Skoch A., Mechl M. Potential of MR spectroscopy for assessment of glioma grading. Clin. Neurol. Neurosurg. 2013;115(2):146–153. (2013 Feb) PubMed
Bulik M., Kazda T., Slampa P., Jancalek R. The diagnostic ability of follow-up imaging biomarkers after treatment of glioblastoma in the temozolomide era : implications from proton MR spectroscopy and apparent diffusion coefficient mapping. Biomed. Res. Int. 2015;2015(2015):641023. PubMed PMC
Chakravarti A., Erkkinen M.G., Nestler U., Stupp R., Mehta M., Aldape K., Gilbert M.R., Black P.M., Loeffler J.S. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin. Cancer Res. 2006;12(15):4738–4746. (2006 Aug 1) PubMed
Dusek L., Muzik J., Maluskova D., Majek O., Pavlik T., Koptikova J., Melichar B., Büchler T., Finek J., Cibula D., Babjuk M., Svoboda M., Vyzula R., Ryska A., Ryska M., Petera J., Abrahamova J. Cancer incidence and mortality in the Czech Republic. Klin. Onkol. 2014;27(6):406–423. PubMed
Ellingson B.M., Bendszus M., Boxerman J., Barboriak D., Erickson B.J., Smits M., Nelson S.J., Gerstner E., Alexander B., Goldmacher G., Wick W., Vogelbaum M., Weller M., Galanis E., Kalpathy-Cramer J., Shankar L., Jacobs P., Pope W.B., Yang D., Chung C., Knopp M.V., Cha S., Van Den Bent M.J., Chang S., Yung W.K. Al, Cloughesy T.F., Wen P.Y., Gilbert M.R. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro-Oncology. 2015;17(9):1188–1198. (2015 Sep) PubMed PMC
Hygino da Cruz L.C., Rodriguez I., Domingues R.C., Gasparetto E.L., Sorensen A.G. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am. J. Neuroradiol. 2011;32(11):1978–1985. (2011 Dec) PubMed PMC
Jiru F., Skoch A., Klose U., Grodd W., Hajek M. Error images for spectroscopic imaging by LCModel using Cramer–Rao bounds. MAGMA. 2006;19(1):1–14. (2006 Feb) PubMed
Jiru F., Skoch A., Wagnerova D., Dezortova M., Hajek M. jSIPRO — analysis tool for magnetic resonance spectroscopic imaging. Comput. Methods Prog. Biomed. 2013;112(1):173–188. (2013 Oct) PubMed
Kao H.-W., Chiang S.-W., Chung H.-W., Tsai F.Y., Chen C.-Y. Advanced MR imaging of gliomas: an update. Biomed. Res. Int. 2013;2013(2013):970586. PubMed PMC
Lee H., Caparelli E., Li H., Mandal A., Smith S.D., Zhang S., Bilfinger T.V., Benveniste H. Computerized MRS voxel registration and partial volume effects in single voxel 1H-MRS. Magn. Reson. Imaging. 2013;31(7):1197–1205. (2013 Sep) PubMed
Provencher S.W. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001;14(4):260–264. (2001 Jun) PubMed
Roy B., Gupta R.K., Maudsley A.A., Awasthi R., Sheriff S., Gu M., Husain N., Mohakud S., Behari S., Pandey C.M., Rathore R.K.S., Spielman D.M., Alger J.R. Utility of multiparametric 3-T MRI for glioma characterization. Neuroradiology. 2013;55(5):603–613. (2013 May) PubMed PMC
Ruben J.D., Dally M., Bailey M., Smith R., McLean C.A., Fedele P. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2006;65(2):499–508. (2006 Jun) PubMed
Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J.B., Belanger K., Brandes A. a, Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005;352(10):987–996. (2005 Mar 10) PubMed
Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J.B., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A. a, Gijtenbeek J., Marosi C., Vecht C.J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J.G., Mirimanoff R.-O. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466. (2009 May) PubMed
Wen P.Y., Macdonald D.R., Reardon D. a, Cloughesy T.F., Sorensen a G., Galanis E., Degroot J., Wick W., Gilbert M.R., Lassman A.B., Tsien C., Mikkelsen T., Wong E.T., Chamberlain M.C., Stupp R., Lamborn K.R., Vogelbaum M. a, van den Bent M.J., Chang S.M. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. 2010;28(11):1963–1972. (2010 Apr 10) PubMed
Zhang H., Ma L., Wang Q., Zheng X., Wu C., Xu B.N. Role of magnetic resonance spectroscopy for the differentiation of recurrent glioma from radiation necrosis: A systematic review and meta-analysis. Eur. J. Radiol. 2014;83(12):2181–2189. (2014 Dec) PubMed
Zhang H., Ma L., Shu C., Wang Y.B., Dong L.Q. Diagnostic accuracy of diffusion MRI with quantitative ADC measurements in differentiating glioma recurrence from radiation necrosis. J. Neurol. Sci. 2015;351(1–2):65–71. (2015 Apr 15) PubMed
Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade
